$35.45
1.785.29%
Dern. MÀJ: Oct 28, 5:00 PM
Caris Life Sciences (CAI) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
fiscal year (2026) a publié ses dernières prévisions le $1.03B - $1.04B pour Caris Life Sciences {{epsDirection}}. La société a prévu un chiffre d'affaires compris entre {{epsPriorRange}} et {{revenueDirection}} pour la période.
Par rapport aux prévisions précédentes, {{newestDate}} {{directionSummary}} ses prévisions de chiffre d'affaires ont été revues à la baisse, passant d'une fourchette précédente de undefined à undefined.
undefined a publié undefined mises à jour de ses recommandations entre undefined et undefined. undefined
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.01 | $-0.02 | $0.07 | $-0.11 |
| Actual | $0.00 | $0.00 | $0.28 | $0.08 |
| Surprise | -100.0% | +100.0% | +300.0% | +172.7% |
| Revenue | ||||
| Estimate | $237.0M | $209.5M | $280.9M | $173.7M |
| Actual | $263.7M | $216.2M | $292.9M | $216.8M |
| Surprise | +11.3% | +3.19% | +4.27% | +24.8% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.02 | $0.11 | $0.04 | $0.10 |
| Revenue | ||||
| Consensus | $254.6M | $294.6M | — | — |
| Trimestre Fiscal | Date de Déclaration | BPA Réel | BPA Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $0 | $0.01 | -100.0 % |
| Q1 | May 7, 2026 | $0 | $-0.02 | 100.0 % |
| Q4 | Feb 26, 2026 | $0.28 | $0.07 | 300.0 % |
| Q3 | Nov 5, 2025 | $0.08 | $-0.11 | 172.7 % |
| Trimestre Fiscal | Date de Déclaration | Revenu Réel | Revenu Estimé | Surprendre % |
|---|---|---|---|---|
| Q2 | Aug 5, 2026 | $263.71M | $236.97M | 11.3 % |
| Q1 | May 7, 2026 | $216.17M | $209.49M | 3.19 % |
| Q4 | Feb 26, 2026 | $292.89M | $280.90M | 4.27 % |
| Q3 | Nov 5, 2025 | $216.83M | $173.69M | 24.8 % |